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Brief Definit ive Report
Tau is a major component of neurofibrillary 
tangles (NFTs) in Alzheimer’s disease (AD) and 
other disorders known as tauopathies. The bur-
den and distribution of NFTs correlate well 
with cognitive decline in AD (Arriagada et al., 
1992; Bancher et al., 1993). In AD, NFTs are 
prominent early in entorhinal cortex and later 
appear in anatomically connected brain regions 
(Braak and Braak, 1995). Cell to cell transmission 
is one hypothesis accounting for this phenom-
enon (Mohamed et al., 2013). Previous studies 
suggest that certain forms of tau released into 
the extracellular space can enter cells and induce 
further tau aggregation (Clavaguera et al., 2009; 
Frost et al., 2009; Guo and Lee, 2011; Kfoury 
et al., 2012; Iba et al., 2013). Tau pathology ap-
pears to spread trans-synaptically from entorhinal 
cortex to hippocampus before marked neuro-
degeneration (de Calignon et al., 2012; Harris 
et al., 2012; Liu et al., 2012). Studies suggest 
that tau can be secreted into the extracellular 
space from neurons independently from cell 
death (Chai et al., 2012; Karch et al., 2012). In 
addition, the elevation of tau in cerebrospinal 
fluid is associated with AD and is linked to A 
deposition (Jack et al., 2013; Maia et al., 2013). 
Despite the fact that extracellular tau may initiate 
synaptic spread of tau pathology, the mechanisms 
regulating neuronal release of extracellular tau are 
not fully understood.
We hypothesized that neuronal activity reg-
ulates release of tau from neurons. To test this 
idea in the setting of mature neuronal networks, 
we used in vivo microdialysis and analyzed the 
kinetics of release and clearance of extracellular 
tau in brain interstitial fluid (ISF).
RESULTS AND DISCUSSION
Increasing neuronal activity  
increases ISF tau in vivo
The technique of in vivo microdialysis enables 
the hourly measurement of endogenous ISF 
tau from wild-type mice. During microdialysis, 
mice are awake and freely moving, allowing for 
the assessment of mechanisms regulating ISF 
tau in the context of normally functioning neu-
ronal networks. We reasoned that if neuronal 
activity is a major regulator of tau release into 
the ISF, altered activity would result in a change 
CORRESPONDENCE  
David M. Holtzman:  
holtzman@neuro.wustl.edu
Abbreviations used: AD, Alz-
heimer’s disease; ISF, inter-
stitial fluid; LDH, lactose 
dehydrogenase; NFT, neuro-
fibrillary tangle; NMDA,  
N-Methyl-d-aspartic acid; PTX, 
picrotoxin; TTX, tetrodotoxin.
Neuronal activity regulates  
extracellular tau in vivo
Kaoru Yamada,1 Jerrah K. Holth,1 Fan Liao,1 Floy R. Stewart,1  
Thomas E. Mahan,1 Hong Jiang,1 John R. Cirrito,1 Tirth K. Patel,1  
Katja Hochgräfe,2,3 Eva-Maria Mandelkow,2,3 and David M. Holtzman1
1Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center,  
Washington University School of Medicine, St. Louis, MO 63110
2DZNE (German Center for Neurodegenerative Diseases), 53175 Bonn, Germany
3CAESAR Research Center, 53175 Bonn, Germany
Tau is primarily a cytoplasmic protein that stabilizes microtubules. However, it is also found 
in the extracellular space of the brain at appreciable concentrations. Although its presence 
there may be relevant to the intercellular spread of tau pathology, the cellular mechanisms 
regulating tau release into the extracellular space are not well understood. To test this in 
the context of neuronal networks in vivo, we used in vivo microdialysis. Increasing neuronal 
activity rapidly increased the steady-state levels of extracellular tau in vivo. Importantly, 
presynaptic glutamate release is sufficient to drive tau release. Although tau release oc-
curred within hours in response to neuronal activity, the elimination rate of tau from the 
extracellular compartment and the brain is slow (half-life of 11 d). The in vivo results 
provide one mechanism underlying neuronal tau release and may link trans-synaptic spread 
of tau pathology with synaptic activity itself.
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and not due to an increased level of total tau proteins inside 
cells (Fig. 2 E).
To further assess whether the treatments we administered 
to increase neuronal activity were not causing cellular damage 
or death, further assays were performed. Neuronal damage, 
including loss of membrane integrity, causes nonspecific re-
lease of intracytoplasmic proteins such as lactose dehydroge-
nase (LDH). Thus, we measured LDH activity in ISF of P301S 
human tau transgenic mice in the presence of PTX adminis-
tered by reverse microdialysis. PTX treatment resulted in a 
two- to threefold increase in ISF human tau in P301S human 
tau transgenic mice (Fig. 2 F), similar to the increase seen in 
mouse tau in wild-type mice. However, PTX did not increase 
LDH activity in ISF (Fig. 2, G and H). The administration of 
pilocarpine is known to cause seizures and excitotoxic injury 
in brain. Systemic administration of pilocarpine resulted in 
seizure activity within 30 min in all mice. It also resulted in an 
increase of ISF tau by 10–15-fold from baseline (Fig. 2 F). 
Unlike PTX, pilocarpine significantly increased LDH activity, 
confirming that excitotoxic injury releases cytoplasmic pro-
teins nonspecifically (Fig. 2, G and H). Pilocarpine adminis-
tration rapidly induced abnormal activation of neurons, as is 
evident by seizure phenotypes observed within 30 min in all 
mice. Nevertheless, the release of LDH by pilocarpine was 
only observed much later after seizures began (7.5 h later; 
Fig. 2 G). These findings strongly suggest that nonspecific re-
lease of cytoplasmic proteins by excitotoxic brain injury is a 
much slower process than the activity-dependent release of 
tau in ISF. Consistent with this data, pilocarpine, but not PTX, 
increased degenerating neurons stained by Fluoro-Jade C 
(unpublished data). Collectively, the data strongly suggests 
that the increase of ISF tau by PTX is due to enhanced neu-
ronal activity and not due to neuronal injury or death caused 
by excitotoxic injury.
in the level of preexisting extracellular tau in vivo. After base-
line tau measurement, hippocampal neurons were locally de-
polarized by briefly exposing them to high K+ perfusion 
buffer via reverse microdialysis. Consistent with an elevation in 
neuronal activity, depolarization rapidly decreased glucose by 
46% (Fig. 1 A) and increased lactate by 171% (Fig. 1 B) in ISF. 
Lactate and glucose rapidly returned to baseline levels after 
wash out. ISF tau increased by 68% from baseline in response 
to high K+ (Fig. 1 C) in the first hour and continued to in-
crease by up to 152% during the wash out period. Once peak 
tau concentrations were reached, ISF tau returned to baseline 
levels over hours. To determine the levels of neuronal activity 
in response to high K+, we used intrahippocampal EEG re-
cording to assess extracellular field potentials during high K+ 
depolarization. The infusion of high K+ resulted in EEG burst-
ing activity (Fig. 1 D).
To stimulate neurons at lower frequency and avoid any 
potential cell injury or death caused by higher activity such as 
is found in prolonged seizures, picrotoxin (PTX), a noncom-
petitive GABAA receptor antagonist was locally and continu-
ously infused in hippocampus via reverse microdialysis at 
relatively low doses. In contrast to EEG bursting activity 
caused by high K+, the low dose of PTX used in this study 
only produced occasional spikes, as assessed by EEG, but no 
epileptiform activity or seizures (Fig. 2 A). This is similar to 
what we have observed previously (Cirrito et al., 2008; Bero 
et al., 2011). PTX decreased glucose by 33% and increased 
lactate by 342% (Fig. 2, B and C) consistent with increased 
neuronal activity. PTX also rapidly increased ISF tau by 149% 
within hours (Fig. 2 D). In contrast to the brief depolarization 
by high K+, the increase of ISF tau was maintained while 
neurons were activated by infusion of PTX. PTX did not 
alter tau levels in hippocampal tissue lysates, further confirm-
ing that increase of ISF tau is due to the release from neurons 
Figure 1. Depolarization increases tau  
in ISF. (A–C) Microdialysis experiments were 
performed in hippocampi of wild-type mice. 
After baseline collection, the regular perfusion 
buffer was switched to high K+ perfusion 
buffer (administration indicated by gray box). 
After 1 h, the buffer was switched back to 
normal perfusion buffer (wash out) and ISF 
collection was continued. Glucose (A), lactate 
(B), and tau (C) in ISF were measured. (n = 5; 
*, P < 0.05; **, P < 0.01). For mice studied in 
A–C, each mouse was investigated indepen-
dently. Any treatment effects were compared 
with baseline values within each mouse. Error 
bars represent SEM. (D) Representative EEG 
trace from one of three mice during depolar-
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neuronal activity—measured by EEG—without causing cell 
death or neurodegeneration (Fig. 2 I; Verges et al., 2011). Consis-
tent with the EEG data, NMDA resulted in a dose-dependent 
increase of ISF tau (Fig. 2 J), suggesting that the degree of 
neuronal activity can determine ISF tau levels. Given that 
To examine how ISF tau can be regulated by the increas-
ing neuronal activity to different degrees, we administered 
increasing doses of N-Methyl-d-aspartic acid (NMDA) in the 
hippocampus. NMDA administered via reverse microdialysis 
at doses of 1–40 µM has dose-dependent effects on excitatory 
Figure 2. Neuronal activity and synaptic activity increase tau in ISF. (A) Representative EEG trace from one of three mice during depolarization 
with high K+ perfusion buffer. 25 µM PTX was delivered directly into the hippocampus of wild-type mice via reverse microdialysis (indicated by dashed 
line). (B–D) Glucose (B), lactate (C), and tau (D) in ISF was measured (n = 6/group). (E) Hippocampal tissue tau levels after PTX reverse microdialysis  
(n = 6/group). (F and G) 25 µM PTX was delivered directly into the hippocampus of P301S human tau transgenic mice via reverse microdialysis for 6 h  
(n = 5). After 6-h washout, the mice were given an i.p. injection of 325 mg/kg pilocarpine hydrochloride (indicated by arrows). Human tau (F) and LDH (G) 
activity in ISF was measured. The mean LDH activity was compared between groups (H; *, P < 0.05). (I) Representative EEG trace from one of three mice 
during various doses of NMDA infusion. (J) The effects of various doses of NMDA delivered by reverse microdialysis on ISF tau was measured (n = 6;  
*, P < 0.05; ***, P < 0.001). (K) The effects of the highly selective mGluR2/3 antagonist LY341495 (administered by reverse microdialysis) on ISF tau was 
measured (n = 6 for LY341495, n = 7 for vehicle). Error bars represent SEM. For mice studied in B–D, F–H, and J–K, each mouse was investigated independently. 
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half-life of A is 2 h (Cirrito et al., 2005), leading to the 
rapid elimination of A by clearance mechanisms. Unlike A, 
tau is known as a very stable protein (Price et al., 2010). This 
raised the possibility that slow turnover might prevent the 
ability to see an effect of TTX on inhibition of basal ISF tau 
release over hours.
To examine the clearance of soluble tau in vivo, the turn-
over rate of tau was kinetically analyzed using transgenic 
mice, which express a non-aggregating form of human tau 
(anti-aggregant mice: 2N4R-tau with K280/PP mutations). 
The expression of human tau in these mice can be quickly 
switched off by doxycycline (Eckermann et al., 2007). These 
mice do not develop tau pathology, allowing us to examine 
the clearance of soluble tau without the influence of tau ag-
gregates (Van der Jeugd et al., 2012; Hochgräfe and Mandelkow, 
2013). To be able to analyze the elimination of ISF tau 
chronically for up to 18 d by microdialysis, mice were divided 
into five groups where human tau expression was switched 
off for the predetermined length of time. One cohort of mice 
was not exposed to doxycycline to determine the initial 
human tau levels before tau switch-off. In vivo microdialysis 
was performed in all groups and levels of ISF tau were as-
sessed over 2 d in each mouse. ISF human tau levels were de-
termined by ELISA. The absolute ISF human tau levels after 
switch-off were normalized to the level of ISF human tau in 
the mice without switch-off. Soluble human tau in the hip-
pocampus where ISF tau was collected was also analyzed at 
the end of microdialysis.
Switch-off specifically decreased human tau in hippo-
campal lysates in a time-dependent manner without chang-
ing endogenous murine tau levels, confirming the specificity 
of switch-off. ISF human tau was also decreased over time, 
whereas lactate levels did not decrease (Fig. 4, A and B). The 
elimination of tau followed first-order kinetics and the half-
life was calculated as 11.1 d for soluble tau in hippocampus 
and 10.9 d for ISF tau, respectively. The clearance rate of tau 
in hippocampal tissue was comparable to a previous report 
assessing total tissue tau (Price et al., 2010; Fig. 4, C and D). 
the EC50 of NMDA receptors is 35 µM in vitro, NMDA con-
centrations of 0.4–4 µM delivered via reverse microdialysis in 
this study should activate only a small percentage of the re-
ceptors (Verges et al., 2011). Nevertheless it is sufficient to 
drive an 70% increase of ISF tau, suggesting that excitatory 
neuronal activity has a significant impact on ISF tau.
Metabotropic glutamate receptors 2/3 (mGluR2/3) are 
expressed at the presynaptic terminal and regulate glutamate 
release. The inhibition of these receptors enhances glutamate 
release from the presynaptic terminals (Cirrito et al., 2008). To 
specifically ask whether the presynaptic excitatory neuronal 
activity modulates ISF tau, LY 341495, a highly selective 
mGluR2/3 antagonist was infused into the hippocampus via 
reverse microdialysis and ISF tau was simultaneously mea-
sured. LY 341495 caused a rapid increase of ISF tau by 80% 
(Fig. 2 K). This data links presynaptic excitatory neuronal ac-
tivity with tau release. Collectively, these data strongly suggest 
that excitatory neuronal activity can rapidly alter the steady-
state levels of extracellular tau levels in vivo.
The effect of TTX on ISF tau levels in vivo
We next asked whether inhibiting neuronal activity alters ISF 
tau. To this end, we infused the voltage-gated sodium channel 
blocker tetrodotoxin (TTX). Surprisingly, TTX did not cause 
a decrease of basal ISF tau within the window of microdialysis 
(Fig. 3 A). In contrast, TTX rapidly decreased endogenous A 
in the ISF by 35% (Fig. 3 B), as we previously reported (Cirrito 
et al., 2005). Confirming that TTX does have an effect on tau 
release, pre-administration of TTX blocked the NMDA- 
induced increase in ISF tau (Fig. 3 C).
The in vivo turnover rate of tau
To try to explain the lack of acute responsiveness of basal ISF 
tau to blocking neuronal activity, we note that the balance 
between cellular release and clearance determines the steady-
state levels of proteins measured by microdialysis. Inhibiting 
synaptic activity reduces ISF A production and release. Re-
duced A release can be visualized quickly, as the in vivo 
Figure 3. TTX does not cause an acute decrease of ISF tau. After baseline ISF tau collection, 5 µM TTX was delivered via reverse microdialysis (indi-
cated by dashed line). The effect of TTX on ISF tau (A; n = 10) and ISF endogenous Ax-40 (B; n = 7; *, P < 0.05) is shown. The effect of preadministration 
of TTX on ISF tau in the presence of 0.4 µM NMDA (C; n = 6–7 per group; *, P < 0.05) is also shown. Both TTX and NMDA were administered by reverse 
microdialysis in C. Error bars represent SEM. Each mouse studied in A–C was investigated independently. Any treatment effects were compared with 
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female P301S human tau transgenic mice and wild-type littermates on B6C3 
background were used for microdialysis studies. Regulatable transgenic mice 
expressing anti-aggregant human full-length tau mice (Tau 2N4R with mu-
tations deltaK280/PP) on C57BL/6 background were generated as previously 
described (Eckermann et al., 2007). Mice were screened for the expression of 
exogenous tau by in vivo bioluminescence imaging of luciferase assay 
(Hochgräfe and Mandelkow, 2013). Individuals with signal intensities >107 p/s 
were selected for switch-off experiments (Van der Jeugd et al., 2012).
In vivo microdialysis. In vivo microdialysis experiments to assess brain ISF 
tau levels from awake and freely moving mice were developed with modifi-
cations of our previously described method (Yamada et al., 2011). A guide 
cannula (Eicom microdialysis) was stereotactically implanted in the left hip-
pocampus under isoflurane anesthesia, and cemented. After implantation of 
the cannula and dummy probes (Eicom microdialysis), mice were habituated 
to microdialysis cages for one more day. After this recovery period, a 2-mm 
1,000-kD cut-off AtmosLM microdialysis probe (Eicom) was inserted 
through the guide cannula. A probe was connected to a microdialysis peristal-
tic pump with two channels (MAB20; SciPro), which was operated in a 
push-pull mode. As a perfusion buffer, 25% human albumin solution (Gemini 
Bio Inc.) was diluted to 4% with artificial CSF (aCSF; 1.3 mM CaCl2, 1.2 mM 
MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122 mM 
NaCl, pH 7.35) on the day of use and filtered through a 0.1-µm membrane. 
For 100 mM high K+ stimulation, 97 mM KCl in aCSF was substituted for 
an equal amount of NaCl. Normal perfusion buffer was switched to high K+ 
perfusion buffer for 1 h. Before microdialysis sample collection, a pump was 
run at the maximum flow rate for at least 1 h. For ISF collection from wild-
type mice, 1 µl/min was used. For ISF human tau collection from transgenic 
mice expressing anti-aggregant human full-length tau (deltaK280/PP), 
0.5 µl/min was used. To avoid tissue damage, the experimental window was set 
from 6 to 48 h after probe implantation. We confirmed that within this time-
frame, ISF tau and Ax-40 concentrations remain stable under constant light 
conditions. ISF samples were collected in a refrigerated fraction collector 
(SciPro) and analyzed by ELISA. 25 µM PTX, 5 µM TTX, 0.4–40 µM 
NMDA, and 100 µM LY341495 were delivered into ISF via reverse microdialy-
sis. For NMDA reverse microdialysis, each dose of NMDA was administrated 
for 5 h in ascending fashion. To assess the effect of TTX on the increase of 
ISF tau by NMDA, 5 µM TTX was delivered by reverse microdialysis for 12 h, 
followed by co-infusion of 0.4 µM NMDA and 5 µM TTX for 12 h.
This observation suggests that extracellular, ISF tau has a much 
longer in vivo turnover rate than A. Thus, even if a substance 
such as TTX decreased endogenous tau release, it would be 
expected to take several days to see such a change.
In summary, our present study describes a mechanistic link 
between neuronal activity and extracellular tau in vivo. In this 
context, we note a very recent in vitro study using primary 
cultured neurons (Pooler et al., 2013) in which neuronal activ-
ity is also linked to increased tau release. Importantly, we found 
that neuronal activity rapidly alters the steady-state levels of 
preexisting ISF tau in vivo. Furthermore, presynaptic glutamate 
release by mGluR2/3 antagonist LY 341495 is sufficient to in-
crease ISF tau, suggesting that presynaptic excitatory neuronal 
activity is linked to tau release. Although neuronal activity in-
creases tau release within hours, tau clearance, which is distinct 
from diffusion to adjacent areas of the brain with lower tau, re-
quires many days. This slow turnover will delay the elimination 
of extracellular tau and, as a consequence, it may affect its ag-
gregation and synaptic transmission of tau pathology. Intrigu-
ingly, not only tau but also many other intraneuronal proteins 
have been identified in the extracellular space of brains, al-
though the mechanism of release of these cytoplasmic proteins 
remains unknown (Lee et al., 2005). Among them are proteins 
such as -synuclein, which contributes to cell to cell transmis-
sion of Parkinson’s disease pathology (Luk et al., 2012). The 
mechanism we report here may have broader implications to 
elucidate mechanisms of release and prion-like spread of intra-
cellular proteins involved in neurodegeneration.
MATERIALS AND METHODS
Compounds. PTX, TTX, NMDA, and pilocarpine were obtained from 
Sigma-Aldrich. LY341495 was obtained from Abcam.
Animals. All animal studies performed were reviewed and approved by the 
Animal Studies Committee at Washington University. 3–5-mo-old male and 
Figure 4. The turnover rate of tau in 
hippocampus and ISF is low. Human tau 
expression in anti-aggregant mice was 
switched off for the indicated lengths of time 
by doxycycline, and human tau (black circle) 
and murine tau (white square) levels in  
hippocampus were measured by ELISA  
(A; n = 5–7/group/time point; **, P < 0.01;  
***, P < 0.001; ****, P < 0.0001). Human tau  
(black circle) and lactate (white square) in  
ISF after switch-off were measured by ELISA  
(B; n = 4–5/group/time point; **, P < 0.01). The 
plot of the common logarithm of percent tau 
in hippocampal lysates or ISF versus time was 
linear in both groups studied. The slope from 
the linear regressions from log (% tau) versus 
time was used to calculate the half-life (t1/2) 
of elimination for tau from hippocampus  
(C) and ISF (D). Each mouse studied in A–D 
was investigated independently. Any treat-
ment effects were compared with baseline 
values obtained from mice studied at time 
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inhibitors [Complete; Roche] and phosphatase inhibitors [PhosSTOP; Roche]). 
The samples were centrifuged at 50,000 g for 20 min at 4°C. The supernatants 
were collected as RAB soluble fractions. The pellets were further homogenized 
by RIPA buffer (150 mm NaCl, 50 mm Tris, 0.5% deoxycholic acid, 1% Triton 
X-100, and 0.5% SDS–25 mm EDTA, pH 8.0, supplemented by protease in-
hibitor [Complete; Roche] and phosphatase inhibitor [PhosSTOP; Roche]). 
Total tau in both RAB and RIPA soluble fractions were combined and used as 
brain soluble tau.
The calculation of half-life. The elimination of tau in brain lysates and 
ISF followed first-order kinetics. Thus t1/2 for tau was calculated with the 
slope, k, of the linear regression (t1/2 = 0.693/k, where k = 2.303k) as we 
previously reported (Castellano et al., 2011).
LDH assay. LDH activity in ISF was determined by Lactate Dehydrogenase 
Activity Assay kit (Sigma-Aldrich). The final measurement [(A450)final] for 
calculating the enzyme activity was normalized by the baseline activities. 
After normalization, mean LDH activity during the 6-h PTX treatment and 
in the last 6-h pilocarpine treatment were compared with baseline.
Statistical analysis. Data in figures represent mean ± SEM. All statistical 
analysis was performed using Prism (version 5.04 for Windows; GraphPad 
Software). Analysis of the effects of drugs compared with vehicle control was 
done by two-way ANOVA with repeated measures. The comparison be-
tween baseline and post-treatment was done by paired Student’s t test. The 
comparison of multiple groups was done by one-way ANOVA. Values were 
considered significant if P < 0.05.
This work was supported by Japan Society for the promotion of Science (K. Yamada) 
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EEG recording. Electrical activity was recorded in the hippocampus sur-
rounding the microdialysis probe similar to Cirrito et al. (2008). In brief, bipo-
lar recording electrodes (Teflon-coated, stainless steel wire, 0.0055-in coated 
OD; A-M Systems) were attached to the shaft of the microdialysis guide can-
nula (BR-style; Bioanalytical) with Super-Fast Epoxy Resin (Elmer’s). Elec-
trodes extended 1 mm from the tip of the guide, so that the electrode tip was 
located at the center of the 2-mm microdialysis membrane. EEG activity was 
assessed using a P511K A.C. pre-amplifier (Grass Instruments), digitized with a 
DigiData 1440 Data Acquisition System (Molecular Devices), and recorded 
digitally using Axoscope 10.2. Compounds were administered directly to the 
brain via reverse microdialysis at a flow rate of 1 µl/min.
Switch-off experiments. 16–17-mo-old transgenic mice expressing anti-
aggregant human full-length tau (deltaK280/PP) were randomly divided into 
five groups. One cohort of mice was not exposed to doxycycline-containing 
food pellets (200 mg/kg; Bio-serv) and ISF was collected for 48 h (0 day 
groups). Other cohorts of mice received doxycycline-containing food pellets 
for 2, 6, 8, or 16 d, respectively before microdialysis. On day 2, 6, 8, or 16, 
in vivo microdialysis was started and ISF samples were collected for 48 h. During 
microdialysis, mice were given doxycycline-containing food pellets. Brains 
were collected on day 4, 8, 10, or 18, respectively, at the end of microdialysis 
experiments. Hippocampus where microdialysis probes were inserted was 
used to determine intracellular human tau levels in hippocampus. Percent-
ages of brain human tau, ISF human tau, and ISF lactate were normalized by 
the mean concentration in 0 day groups.
Pilocarpine injection. Mice received a low dose of methyl scopolamine 
(1 mg/kg) to reduce peripheral cholinergic effects. After 30 min, mice were given 
i.p. injection of 325 mg/kg pilocarpine hydrochloride. All animals injected 
with pilocarpine displayed motor seizure phenotype. 15 min after pilocarpine 
injection, the mice were injected with pentobarbital to terminate seizures.
Tau ELISA. The tau concentration in media of brain slice culture and ISF 
of wild-type mice was analyzed in a tau sandwich ELISA with Tau-5 as a 
coating antibody (gift from L. Binder, Northwestern University, Evanston, 
IL) and biotinylated BT-2 (Thermo Fisher Scientific) as a detection antibody 
as previously described (Yamada et al., 2011). Human tau in ISF and brains 
was measured by a human tau-specific sandwich ELISA with Tau-5 as a coat-
ing antibody and biotinylated human specific HT-7 (Thermo Fisher Scien-
tific) as a detection antibody. Murine endogenous tau in brains was measured 
by a sandwich ELISA with HJ9.2 as a coating antibody and biotinylated tau 
antibodies (HJ8.7) as a detection antibody. HJ8.7 and HJ9.2 are in-house 
mouse monoclonal antibodies that recognize the N-terminal domain of tau 
(epitope of HJ8.7: residues 118–122; epitope of HJ9.2: residues 4–8). The 
human tau levels in samples were determined by subtracting background sig-
nals from wild type in Tau-5/HT7 ELISA.
Ax-40 ELISA. Ax-40 ELISA was done as previously described (Cirrito 
et al., 2008). Background determined by signal from the microdialysis perfu-
sion buffer was subtracted.
Glucose and lactate measurements. Glucose and lactate concentration 
in ISF and media was determined by YSI2700 biochemistry analyzer (YSI 
Life Sciences). Glucose was used as a marker of substrate utilization, and lac-
tate was used as a marker of neuronal activity (Bero et al., 2011).
Brain extraction. Mice were perfused with chilled PBS-heparin. Brains were 
dissected for biochemical analysis and kept at 80°C until analyzed. To analyze 
tau after PTX infusion, left (exposed to PTX by reverse microdialysis) and right 
hippocampi were dissected at 4.5 h after PTX infusion where both ISF lactate 
and tau showed the highest increases from baseline. Tau in hippocampal lysates 
was determined by Tau-5/BT2 ELISA. Contralateral hippocampus (right) was 
used as a control. In switch-off experiments, hippocampus was weighed and 
homogenized in RAB buffer (100 mM MES, 1 mM EDTA, 0.5 mM MgSO4, 
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